Navigation Links
Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
Date:1/7/2008

HONOLULU, Jan. 7 /PRNewswire/ -- Hawaii Biotech, Inc. announced today that it has been notified by the United States Food and Drug Administration (FDA) that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results of the trial may be available by the end of 2008.

HBI develops subunit vaccine candidates that have been shown to elicit protective immune responses in animal efficacy models for diseases such as West Nile, dengue, influenza, Ebola, malaria and tick-borne encephalitis.

"The West Nile vaccine will be the first candidate to enter clinical trials for Hawaii Biotech. This is a substantial milestone for the company as it is a novel vaccine candidate with which the FDA has had little experience. Receiving this notification from the FDA that we may proceed to human clinical trials is the first step in proving our technology in a clinical setting and to the scientific community," said Dr. Carolyn Weeks-Levy, President and CEO of HBI.

Currently there is no vaccine for the prevention of West Nile disease in humans; a disease that has caused over 25,000 cases of disease and over 1000 deaths since the virus was introduced in the U.S. in 1999.

About Hawaii Biotech, Inc.

Hawaii Biotech is a privately held biotechnology company focused on the research and development of prophylactic vaccines for infectious diseases. Hawaii Biotech has developed a proprietary protein production platform that has application to the production of proteins for use as antigens in infectious disease vaccines. In addition, to its work on a dengue vaccine, the company is also developing vaccines for West Nile virus and seasonal influenza. Haw
'/>"/>

SOURCE Hawaii Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
4. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
10. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
11. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., , MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswi...daq: ALXA ) announced today that its corporate pr...nual Piper Jaffray Health Care Conference on Wedne... The presentation will be webcast from The New Yor...y Thomas B. King, Alexza President and CEO. ,...
(Date:11/19/2009)..., , ABBOTT PARK, Ill., Nov. 19 /PRNewswire-...bott (NYSE: ABT ) as one of its Most Admired Cor... The Deal honored Abbott as its Most Admired De...trategic use of acquisitions and divestitures sinc... has reshaped its business portfolio with a focus ...
(Date:11/19/2009)..., , NEW YORK, Nov. 19 As ...unning noses is here. Here,s more on preparing you...il-Janssen Pharmaceuticals Inc. at: ,, http:...nRfCsbxc9R2VXAOIF ,, Medialink is a division...cess video, audio, text, graphics and photos at ...
Breaking Medicine Technology:Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Regado Biosciences Expands Medical Advisory Board 13085 1Regado Biosciences Expands Medical Advisory Board 13085 2Regado Biosciences Expands Medical Advisory Board 13085 3Regado Biosciences Expands Medical Advisory Board 13085 4Cytokine PharmaSciences Initiates Phase I Study of Oral Anti Inflammatory Agent CPSI 2364 4746 1Cytokine PharmaSciences Initiates Phase I Study of Oral Anti Inflammatory Agent CPSI 2364 4746 2Elder Boom Will Be Felt Worldwide 52094 1Elder Boom Will Be Felt Worldwide 52094 2
...007 /PRNewswire-FirstCall/ --,Telik, Inc. announce...Phase 2 trial of the triplet combination of TELCYT...aclitaxel will be,presented at the 98th annual mee...ch (AACR) in Los Angeles. Preclinical studies of,c...ncer cell growth,inhibition with TELCYTA in combin...
...pril 11, 2007,/PRNewswire-FirstCall/ -- Rigel Phar... on R788, which is currently in ongoing,Phase 2 cl...ITP),rheumatoid arthritis (RA) and lymphoma patie...at blocks the activation of mast cells,macrophage...responses and tissue damage. , Rigel commenced an ...
Other Medicine Technology:Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 2Telik Announces Telcyta Clinical and Preclinical Presentations at,AACR Meeting 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4
(Date:11/21/2009)...Nov. 21 Tonight, in a p...Senator Reid,s version of the government takeover ...ems included in this bill; like the public option,...nt funding for elective abortion, which is the mos...the bill provides subsidies for private plans that...
(Date:11/21/2009)...ll provides for an unprecedented expansion of fede...f it is not for preserving and protecting human li...d." Charmaine Yoest ,, WASHINGTON, Nov. 21 /...e Action President and CEO Dr. Charmaine Yoest res...g the following statement: ,, "This was a pro-...
(Date:11/21/2009)... Nov. 21 A regional ini...rciasis (river blindness) in the Americas has subs... recent years, as evidenced by a 31% decrease in t...istration in six endemic countries. Results were ...merican Society of Tropical Medicine and Hygiene (...
(Date:11/21/2009)...vember 21, 2009 Test Tes...t Test Test Test Test Test Test Test,Test Test Tes...t Test Test,Test Test Test Test Test Test Test Tes...st More test More test More test More test More te...st More test More test More,test More test , , ...
(Date:11/21/2009)... Innovative medical apparel company launches men,... San Clemente, Calif. (PRWEB) Novemb...h medical apparel, today announced the launch of i... 2009, a leading international trade fair for the ...lita inaugurates its men,s collection with three v...
Breaking Medicine News(10 mins):Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3
...en as people struggle to cope with economic uncert...,s still possible to live a joyful, vital "best" l...y years, Harvard trained psychiatrist Dr. Richar...how to find the "best" in our living, the despair ...
... John K. Davis, II has been named Senior Vice Pre...an Board of Internal Medicine (ABIM), effective Ap...will work closely with senior management and the B...gy initiatives that support ABIM,s mission to ensu...
...e Mashour and David Glick highlight the serious is...view published by F1000 Medicine Reports. , Consc...y distressing condition leading to post-operative ...esthesia and Pain Management, writes that intra-op...
... 2 Helen of Troy Limited (Nasdaq: HELE ), desig...e personal care and household consumer products, t...reviously reported agreement to acquire the global... a trusted reputation with stylists and consumers ...
... 2 Spring is in the air, and along with it, tree,...y sufferer,s immune system a curve ball. But the A...Balanced Living magazine uncovers five other su... allergens as foreign bodies and launches an infla...
... InVitria,s Recombinant Albumin-DX eliminates s...d enhances diagnostic performance by improving spe... CO (PRWEB) April 2, 2009 -- Addressing significan... albumin products. InVitria,s Recombinant Albumin-...
Other Medicine News:Health News:Psychiatrist Dr. Richard Esser: How to Find the Best of Life in the Worst of Times 2Health News:John K. Davis, II to Join the American Board of Internal Medicine as Chief Information Officer 2Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 2Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 3Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 4Health News:Surprising Allergy Triggers May Be Making Your Spring Sniffles Worse 2Health News:InVitria Announces Launch of Recombinant Albumin for Diagnostics 2
Williams Eye Speculum - 14 mm
Castroviejo Speculum - 15 mm
Snare Wire
Thorton Fixation Ring 13 mm
Medicine Products: